Welcure Drugs & Pharmaceuticals Board of Directors

Get the latest insights into the leadership at Welcure Drugs & Pharmaceuticals. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Yogeshkumar PrajapatiNon Executive Independent Director
Bhumika PradhanNon Executive Independent Director
Ravi ThakorNon Executive Independent Director
Chintan DidawalaManaging Director
Palak JainCompany Secretary & Compliance Officer

Welcure Drugs & Pharmaceuticals Share price

WELCURE

0.29

0.01 (3.57%)
Last updated on 4 May, 2026 | 14:58 IST
Today's High

0.29

Today's Low

0.27

52 Week Low

0.23

52 Week High

1.44

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Welcure Drugs & Pharmaceuticals FAQs

The board at Welcure Drugs & Pharmaceuticals consists of experienced professionals, including Yogeshkumar Prajapati, Bhumika Pradhan, and others, overseeing the company’s strategic and corporate governance.

Directors at Welcure Drugs & Pharmaceuticals are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Yogeshkumar Prajapati is the current chairman at Welcure Drugs & Pharmaceuticals.

Executive directors at Welcure Drugs & Pharmaceuticals are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Welcure Drugs & Pharmaceuticals adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Welcure Drugs & Pharmaceuticals, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost